Bioject Medical Technologies collaborates with MPI Research to explore drug and device opportunities

Jan 5 2010

Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems, today announced that it has established a strategic alliance with MPI Research, a leading pre-clinical research organization with experience in the development of injectable therapeutics.

“Bioject and MPI Research share an innovative and entrepreneurial spirit that creates a synergy vital to our industry. It is a pleasure to collaborate with a company that has such highly-developed technological expertise and strategic vision.”

The strategic alliance creates a preferred partnership relationship which allows Bioject to gain access to a range of capabilities and resources needed for the company to explore our drug+device opportunities, including access to pharmacologic, analytical, safety and other preclinical testing resources available at MPI Research. The strategic alliance offers MPI Research the opportunity to provide Bioject’s needle-free technology as an alternate delivery option to current drug/biologic manufacturers who may be interested in seeking a more highly competitive and differentiable drug+device brand. This alliance also increases the possibility that Bioject and MPI Research may be able to secure government sponsored grants or funding directed at improvements in drug+device or vaccine+device based treatments, which could also lead to potential new drug+device combinations.

“We look forward to our new strategic alliance with MPI Research, which adds the much needed resource capabilities that we have been seeking as a first step in advancing our new drug+device business strategy,” said Ralph Makar, Bioject’s President and CEO. “This is a positive step forward for both organizations and allows each partner to leverage the strengths, resources and technologies available that we believe will lead to additional new business opportunities for both companies. We are excited and enthusiastic about the potential for the future,” said Mr. Makar.

CEO and Chairman of MPI Research, Bill Parfet, agrees. “Bioject and MPI Research share an innovative and entrepreneurial spirit that creates a synergy vital to our industry. It is a pleasure to collaborate with a company that has such highly-developed technological expertise and strategic vision.”